J&J Says 'Evidence is Insufficient to Establish a Causal Relationship Between These (adverse) Events'

The New England Journal of Medicine (NEJM) published a Correspondence submitted by researchers associated with Johnson & Johnson and Janssen Pharmaceuticals on April 16, 2021, Thrombotic Thrombocytopenia after Ad26.COV2.S Vaccination — Response from the Manufacturer.

This letter stated 'At this time, evidence is insufficient to establish a causal relationship between these (adverse) events and the Ad26.COV2.S vaccine (Janssen COVID-19 Vaccine).'

Johnson & Johnson highlighted that out of more than '75,000 participants in the clinical trial program for its vaccine, one case of CVST emerged. And 'It is important to note that the incidence of CVST associated with low platelets is unknown and is considered by the FDA and the CDC to be extremely low.'

'We continue to work closely with experts and regulators to assess the data, and we support the open communication of this information to health care professionals and the public,' concluded this NEJM Correspondence.